Total Facility Solutions wins contract from Novartis

Published: 14-Sep-2011
Manufacturing Finance

To install hygienic process piping at Vaccines and Diagnostics plant in Holly Springs, NC

Total Facility Solutions, a specialist contractor focused on critical process infrastructure, has been awarded a contract to install hygienic process piping at the Novartis Vaccines and Diagnostics campus in Holly Springs, North Carolina, US.

The order is part of Novartis’ US$36m expansion of its pandemic and seasonal flu production facility, announced last December, which will create 100 new jobs at the Holly Springs development lab and pilot plant.

‘This selection to fabricate and install process piping at Novartis affirms the strength of our model for serving the life science business,’ said Joe Cestari, president of Total Facility Solutions.

‘Having invested heavily in our own North Carolina facility in 2009, we bring the infrastructure, industry expertise and experienced personnel necessary to execute on this project on time, on budget and to specification.’

The project will be operated out of Total Facility Solutions’ Raleigh, NC location, using its 4,000ft2 clean manufacturing space to complete all building work. This plant is equipped with the latest technology for orbital welding and meets stringent market requirements while facilitating just-in-time delivery to the construction site. Bovis Lend Lease and Novartis’ project managers are overseeing the project.

Total Facility Solutions (TFS) provides turnkey facilities contracting services including high-purity piping, gas and chemical systems, ultra-high purity water systems, tool and equipment installation, clean utilities, and electrical services to the semiconductor, electronics, nanotechnology, photovoltaic, life sciences, mission critical, and renewable energy industries.

See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Containment

Clean environments: meeting modern drug production challenges

Read more
New medicinal therapies are seeing rapid development but face many price pressures and regulatory challenges. George Wiker, VP, M+W Group and Kurt Gilson, VP, Western US, Total Facility Solutions, discuss the impact on facility design

Trending Articles

  1. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
  3. Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
  4. Lonza delivers strong performance in Q1 2026 in line with expectations and confirms full-year Outlook 2026 Basel, Switzerland, 8 May 2026 – In its qualitative Q1 2026 business update, Lonza1 reported a strong performance across its CDMO business in line with the expected trajectory for Full-Year 2026. As expected, due to a lower prior year base, campaign timing and product releases, and planned site shutdowns, CER sales growth and CORE EBITDA margin will be notably stronger in the first half of 2026 than in the second half
  5. Piramal Pharma Solutions unveils state-of-the-art payload-linker suite at its Riverview, Michigan facility The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialised solutions for payload-linkers. This cutting-edge suite will significantly enhance the company’s ability to support global payload-linker development and manufacturing and help partners bring complex therapies like antibody-drug conjugates (ADCs) and other bioconjugates to market

Upcoming event

Cleanroom Technology Conference UK

20-21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Containment

Clean environments: meeting modern drug production challenges

New medicinal therapies are seeing rapid development but face many price pressures and regulatory challenges. George Wiker, VP, M+W Group and Kurt Gilson, VP, Western US, Total Facility Solutions, discuss the impact on facility design
Manufacturing

Total Facility Solutions builds dedicated hygienic fabrication plant

Company will be better positioned to support the high purity piping needs of numerous life science customers
Manufacturing

Replacing discontinued OEM degasser modules

Biotech Fluidics introduces direct replacement OEM degasser modules based on upgraded vacuum technology to support continued fluidic instrument supply without costly redesigns
Manufacturing

etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage

etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Manufacturing

CARBOGEN AMCIS introduces SPRINT for early-phase development

A new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour
Manufacturing

FUJIFILM Cellular Dynamics opens new iPSC manufacturing facility in US

The new site will serve as the company's headquarters and will increase Fujifilm's capacity for induced pluripotent stem cell development and manufacturing, as demand increases with new approach methods in research
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

From bespoke to scalable: closing the manufacturing gap in advanced therapeutics

Dr Kevin Robinson (KSR) spoke to Cytiva’s Nicolas Pivet (NP), Vice President of Manufacturing and Digital Solutions, to find out how digitalisation and scalable manufacturing platforms are shaping the next phase of advanced therapeutics
Subscribe now